G protein-coupled receptor kinases (GRKs)

Overview

« Hide

G protein-coupled receptor kinases, epitomized by βARK, are involved in the rapid phosphorylation and desensitization of GPCR. Classically, high concentrations of β2-adrenoceptor agonists binding to the receptor lead to the consequent activation and dissociation of the heterotrimeric G protein Gs. Gαs activates adenylyl cyclase activity, while Gβγ subunits perform other functions, one of which is to recruit βARK to phosphorylate serine/threonine residues in the cytoplasmic tail of the β2-adrenoceptor. The phosphorylated receptor binds, with high affinity, a member of the arrestin family (ENSFM00250000000572), which prevents further signalling through the G protein (uncoupling) and may allow interaction with scaffolding proteins, such as clathrin, with the possible consequence of internalization and/or degradation.

Subfamilies

GtoImmuPdb view: OFF

The Kinome image shown here was obtained from Chartier et al. (2013, <a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740139/figure/fig-4/' target='_blank'>Figure 4</a>) <a href='https://www.ncbi.nlm.nih.gov/pubmed/23940838' target='_blank'>https://www.ncbi.nlm.nih.gov/pubmed/23940838</a> and has been annotated to show the kinases that are targeted by currently approved kinase inhibitor drugs (last updated in April 2018).

Comments

« Hide

Loss-of-function mutations in RHOK or retinal and pineal gland arrestin (SAG, P10523) are associated with Oguchi disease (OMIM: 181301), a form of congenital stationary night blindness.

How to cite this family page

Database page citation:

G protein-coupled receptor kinases (GRKs). Accessed on 10/12/2018. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=283.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. (2017) The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol. 174 Suppl 1: S272-S359.